30 closest matches · ranked by relevance
Amoebic Dysentery · Giardiasis
Primary: Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose…
Trichuris Infection · Helminthiasis
Primary: Cure Rate — 1; 31; 6; 40 Participants
Tropical Enteropathy
Primary: Difference in the Urinary L:M Ratio Before and After the Intervention — -0.01; 0.02 Ratio of lactulose-to-mannitol (L:M) exc
Falciparum Malaria
Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants
Cryptosporidium Infection, Cryptosporidiosis
Primary: Percentage of Participants With Cryptosporidium Infection From 72 Hours to 10 Days Post ABO809 Oral Administration — 50; 57.1; 60.0 percentage of participants
Malaria · Intermittent Preventive Treatment
Primary: Risk of Parasitaemia (Unadjusted by Genotyping) — 23; 87; 164; 147 Participants
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Schistosomiasis · Schistosomiasis Mansoni · Schistosoma Japonicum Infection
Primary: Treatment Efficacy — 96; 98; 96; 98 percentage change
Clostridium Enterocolitis · Pseudomembranous Colitis
Primary: Nitazoxanide — 27 participants
Malaria
Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants
P Vivax · Malaria, Vivax
Primary: Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled — 61; 88; 90 participants
Malaria
Primary: Number of Patients With Adequate Clearance of Parasites and Symptoms — 110 Participants
Trichuriasis · Hookworm Infections
Primary: Cure Rate Against T. Trichiura and Hookworm Infections — 4; 2; 4; 5 Participants
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Plasmodium Falciparum, Malaria
Primary: Infection Rate — 5; 6; 3; 0 Participants
Clostridium Difficile Infection
Primary: Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) Population — 10; 0 Participants
Healthy Subjects
Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio
Malaria Diagnosis
Primary: Malaria Diagnosis Using RealAmp and Microscopy. — 42; 153; 0; 1 Participants
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants
Infectious Diarrhoea
Primary: Time to Last Unformed Stool (TLUS) — 59.3; 51.4; 57.4 hours
Dysentery · Diarrhea · Enteric Campylobacteriosis
Primary: Campylobacteriosis — 13; 11 Participants
Diarrhea
Primary: Part A: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal — 0; 0; 0; 0 adverse events
ETEC Diarrhea
Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea
Malaria
Primary: Malaria Status — 18; 16 Participants
Complicated Intra-abdominal Infection
Primary: Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Test-of-Cure Visit — 39; 41; 24; 3 participants
Prematurity · Intestinal Permeability
Primary: Intestinal Permeability — 0.0731; 0.0720 ratio — p=0.932
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
Traveler's Diarrhea
Primary: Time to Last Unformed Stool (TLUS) — 44.3; 40.3 hours
Malaria Anaemia
Primary: Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms — 93.4; 93.7 g/L